Ren Life Sciences Partners II L.P.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
Pre-open
Investors
—
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Ren Life Sciences Partners II L.P. is a Guernsey limited partnership organized in 2026 that filed a Form D with the SEC on September 3, 2026, describing itself as a other investment fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(1), Section 3(c)(7) and covers equity and pooled investment fund interests. Ren Life Sciences Partners II L.P. reported that the first sale had not yet occurred as of the Form D filed September 3, 2026, so no amount sold or investor count is on file. The total offering amount is listed as indefinite. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing checks both Section 3(c)(1), which caps the fund at 100 beneficial owners, and Section 3(c)(7), which requires every investor to be a qualified purchaser, generally an individual with at least $5 million in investments. A fund normally relies on one or the other. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Pacenote Capital LLC (CRD 000305007), associated with Broker as the recipient of sales compensation soliciting in all states. The issuer's address of record is 2nd Floor, Dorey Court, Elizabeth Avenue, St. Peter Port, Y7 GY1 2HT.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Sep 3, 2026
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
pre_sale
Latest event New filer · Sep 3, 2026
SEC.govFund family Part of the Ren Life Sciences Partners family: 2 vehicles across 2 generations · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- 1 filing event with values and deltas, latest 2026-09-03, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Ren LS General Partner II Limited
Director · St. Peter Port, Y7
The general partner of the Issuer
Ian Smith
Director · St. Peter Port, Y7
Director of the general partner of the Issuer
Marc Tanguy
Director · St. Peter Port, Y7
Director of the general partner of the Issuer
Andrew Henton
Director · St. Peter Port, Y7
Director of the general partner of the Issuer
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Pacenote Capital LLCCRD 000305007 on BrokerCheck
Associated broker-dealer: Broker · Austin, TX · Soliciting in all states
Questions About Ren Life Sciences Partners II L.P.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Ren Life Sciences Partners II L.P.?
Ren Life Sciences Partners II L.P. is a Guernsey limited partnership organized in 2026 that filed a Form D with the SEC on September 3, 2026 as a other investment fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(1), Section 3(c)(7) for an offering of equity and pooled investment fund interests.
Is Ren Life Sciences Partners II L.P. legit?
AltStreet does not rate legitimacy; it reports the public record. Ren Life Sciences Partners II L.P. filed a Form D with the SEC on September 3, 2026 claiming Rule 506(b), Section 3(c), Section 3(c)(1), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. No sales had been reported as of that notice. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Ren Life Sciences Partners II L.P. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Ren Life Sciences Partners II L.P. claimed Rule 506(b), Section 3(c), Section 3(c)(1), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Ren Life Sciences Partners II L.P. raised?
Ren Life Sciences Partners II L.P. reported that the first sale had not yet occurred as of the Form D filed September 3, 2026, so no amount sold or investor count is on file. The total offering amount is listed as indefinite.
Who can invest in Ren Life Sciences Partners II L.P.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing checks both Section 3(c)(1), which caps the fund at 100 beneficial owners, and Section 3(c)(7), which requires every investor to be a qualified purchaser, generally an individual with at least $5 million in investments. A fund normally relies on one or the other. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Ren Life Sciences Partners II L.P.?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Ren Life Sciences Partners II L.P. and how are they paid?
The Form D names Pacenote Capital LLC (CRD 000305007), associated with Broker as the recipient of sales compensation soliciting in all states.
Who is behind Ren Life Sciences Partners II L.P.?
The Form D lists 4 related persons: Ren LS General Partner II Limited, director (The general partner of the Issuer); Ian Smith, director (Director of the general partner of the Issuer); Marc Tanguy, director (Director of the general partner of the Issuer); Andrew Henton, director (Director of the general partner of the Issuer). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Ren Life Sciences Partners II L.P. located?
The issuer's address on its SEC filings is 2nd Floor, Dorey Court, Elizabeth Avenue, St. Peter Port, Y7 GY1 2HT. Its phone number of record is 44 1481 731750. It is organized under the laws of Guernsey.
How long is the Ren Life Sciences Partners II L.P. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
How large is Ren Life Sciences Partners II L.P.?
The issuer declined to disclose its net asset value range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.